Piramal Pharma has moved toward full ownership of Yapan Bio by exercising its call option for the remaining 26% equity stake. But the company’s November 18, 2026 disclosure does not say the share transfer is complete. The acquisition price and effective transfer date are still being finalized.
That leaves a clear distinction between the decision announced and the ownership outcome expected. Piramal currently holds 74% of Yapan. Its holding is expected to reach 100%, making Yapan a wholly owned subsidiary, upon completion of the proposed transaction.
What the committee approved
The Administrative Committee of Piramal Pharma’s board, acting under authority delegated by the board, approved exercising the call option to acquire the balance stake from Yapan’s existing shareholders. The filing says discussions with those shareholders are under way on matters needed to complete the transaction.
A call option in this disclosure concerns the right to acquire shares in the subsidiary. It is not an announcement of an exchange-traded options position in Piramal Pharma’s own stock. The relevant corporate event is the proposed purchase of Yapan equity.
The price and completion date remain open
Piramal explicitly says the final acquisition terms, including consideration and the effective date of share transfer, are yet to be finalized. A precise purchase price or a closing deadline cannot therefore be drawn from this announcement.
The company says it will make further required disclosures upon execution of definitive documentation and completion of the proposed transaction. Those documents and the completion update will matter more for assessing the final economics than treating the option exercise itself as proof that the acquisition has closed.
What Yapan does, and what this filing does not claim
Yapan is a contract development and manufacturing organisation. According to Piramal’s filing, it specialises in process development, characterisation and Phase I/II GMP manufacturing services for vaccines and biologics. These describe its services, not a newly announced product approval or a completed clinical trial.
The immediate development is a step toward buying the minority holding in an existing subsidiary, rather than entering an entirely new business through this announcement. The filing gives no quantified revenue uplift, profit contribution or new customer contract from the proposed purchase. Full ownership remains the expected result of completion, not the current status reported here.
Source: Piramal Pharma’s November 18 exchange disclosure. The accompanying image is an original conceptual illustration, not a photograph of Yapan’s facilities.
